EANM guideline on quality risk management for radiopharmaceuticals

Nic Gillings, Olaug Hjelstuen, Martin Behe, Clemens Decristoforo, Philip H. Elsinga, Valentina Ferrari, Oliver C. Kiss*, Petra Kolenc, Jacek Koziorowski, Peter Laverman, Thomas L. Mindt, Meltem Ocak, Marianne Patt, Sergio Todde, Almut Walte

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

1 Citation (Scopus)
7 Downloads (Pure)

Abstract

This document is intended as a supplement to the EANM "Guidelines on current Good Radiopharmacy Practice (cGRPP)" issued by the Radiopharmacy Committee of the EANM (Gillings et al. in EJNMMI Radiopharm Chem. 6:8, 2021). The aim of the EANM Radiopharmacy Committee is to provide a document that describes how to manage risks associated with small-scale "in-house" preparation of radiopharmaceuticals, not intended for commercial purposes or distribution.

Original languageEnglish
Pages (from-to)3353-3364
Number of pages12
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Volume49
Early online date7-Apr-2022
DOIs
Publication statusPublished - Aug-2022

Keywords

  • Risk assessment
  • Radiopharmaceuticals
  • Quality assurance

Cite this